Thyrotoxicosis Diagnosis and Management

Pathophysiology and Clinical Significance

• The combination of low/suppressed TSH with elevated free T4 or total T3 represents thyrotoxicosis, where excess thyroid hormone suppresses the pituitary's TSH production through negative feedback 1.
• Thyrotoxicosis due to thyroiditis is the most common cause in patients on immune checkpoint inhibitors, occurring more frequently with anti-PD1/PD-L1 drugs than anti-CTLA-4 agents 1.

Differential Diagnosis

• Painless thyroiditis presents with low/normal TSH and high free T4 or T3, typically occurring an average of one month after starting immunotherapy 1.
• This is a self-limiting process that leads to permanent hypothyroidism after an average of 1 month following the thyrotoxic phase 1.

Diagnostic Workup Algorithm

• Measure TSH, free T4, and free T3 to establish the pattern and severity 1.
• Check thyroid peroxidase (TPO) antibodies to evaluate for autoimmune thyroid disease 1.
• Low or absent uptake indicates thyroiditis; high uptake indicates Graves' disease or toxic nodular goiter 1.

Management Based on Etiology

• Conservative management during the thyrotoxic phase is sufficient—no antithyroid drugs are needed 1.
• Non-selective beta blockers, preferably with alpha receptor-blocking capacity, may be needed for symptomatic patients to control heart rate, tremor, and anxiety 1.
• Initiate thyroid hormone replacement at the time of hypothyroidism diagnosis, which typically occurs 1 month after the thyrotoxic phase and 2 months from immunotherapy initiation 1.

Special Considerations

• For patients on immune checkpoint inhibitors, continue immunotherapy in most cases—high-dose corticosteroids are rarely required for thyroid dysfunction 2.
• Prolonged TSH suppression (<0.1 mIU/L) increases risk for atrial fibrillation, especially in elderly patients, and potential cardiovascular mortality 2.